Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS (Details)

v3.24.0.1
SUBSEQUENT EVENTS (Details) - Subsequent event - GAVRETO (pralsetinib) - Blueprint
$ in Millions
Feb. 22, 2024
USD ($)
Subsequent Event [Line Items]  
Asset acquisition, expected price $ 15.0
Minimum  
Subsequent Event [Line Items]  
Potential tiered royalties (as a percentage) 10.00%
Maximum  
Subsequent Event [Line Items]  
Potential tiered royalties (as a percentage) 30.00%
First commercial sale  
Subsequent Event [Line Items]  
Asset acquisition, expected price $ 10.0
First anniversary of the closing date  
Subsequent Event [Line Items]  
Asset acquisition, expected price 5.0
Commercial milestones  
Subsequent Event [Line Items]  
Potential milestone payments 97.5
Regulatory milestones  
Subsequent Event [Line Items]  
Potential milestone payments $ 5.0